The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.
PCS IX
NCT02685397
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Prostate |
Dr. Fabio Cury
Josie Pepe
514-934-1934 poste 48186
|
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
EORTC-1333-GUCG / PEACE III
NCT02194842
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Prostate |
Dr. Frédéric Pouliot
Pascale Lévesque-Bernier
418-525-4444 poste 16860
|
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate
PCS VI
NCT02303327
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Prostate |
Dr. Tamim Niazi
Ashley Feng
514-340-8222 poste 26510
|
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.
PCS IX
NCT02685397
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Prostate |
Dr. Marjory Jolicoeur
Geneviève Bujold
450-466-5000 poste 2164
|
A Randomized Phase II Trial Evaluating Hight Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
PR.19
NCT02960087
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Prostate |
Dr. Éric Vigneault
Josée Allard
418-525-4444 poste 16730
|
The Role of Stereotactic Body Radiotherapy in the Managementof Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial
PCS IX
NCT02685397
Recruiting
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
Prostate |
Dr. Rafika Dahmane
Marie-Ève Caron
819-697-3333 poste 63238
|
A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer
IND.223
NCT02905318
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Prostate |
Dr. Cristiano Ferrario
|
A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234
IND.234B
NCT03385655
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Prostate |
Dr. Fred Saad
Amal Nadiri
514-890-8000 poste 26074
|
A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234
IND.234C
NCT03385655
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Prostate |
Dr. Fred Saad
Amal Nadiri
514-890-8000 poste 26074
|
Étude de phase I-II d'une radiothérapie stéréotaxique hypofractionnée par le cyberknife® pour le traitement de récidive biochimique de cancer de la prostate après un traitement de radiothérapie.
Cyberknife® prostate
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Prostate |
Dr. Jean-Paul Bahary
Diane Trudel
514-890-8000 poste 11181
|
Groupe d'étude en oncologie du Québec